// App-Quantinova.ai

e23161 : Structure-activity relationships (SAR) and mechanistic analysis of clinical-stage anti-cancer small molecule ONC201 analogues.

Researchers

Presenter

  • Jessica Wagner

Principal Investigators

  • Gary Olson

  • Bhaskara Rao Nallaganchu

  • Richard Pottorf

  • Martin Stogniew

  • Lee Schalop

  • Wolfgang Oster

  • Mathew Garnett

  • Ultan McDermott

  • Cyril Benes

  • Rohinton Tarapore

  • Joshua E. Allen

  • Wafik S. El-Deiry

Medical Centers

  • Fox Chase Cancer Center, Philadelphia, PA

  • Provid Pharmaceuticals Inc, Monmouth Junction, NJ

  • Provid Pharmaceuticals Inc, Monmouth Junction, NJ

  • Oncoceutics, Philadelphia, PA

  • Wellcome Trust Sanger Institute, Cambridge, United Kingdom

  • Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • United States

  • United Kingdom

Companies

  • Wellcome Sanger Inst

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • TIC 10

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved